Crinetics Pharmaceuticals (CRNX) Non-Current Deferred Tax Liability (2019 - 2024)

Crinetics Pharmaceuticals' Non-Current Deferred Tax Liability history runs 4 years deep, the most recent figure standing at $9.8 million for Q4 2024.

• On a quarterly basis, Non-Current Deferred Tax Liability changed 0.49% year-over-year to $9.8 million in Q4 2024; TTM through Dec 2024 was $9.8 million, a 0.49% change from a year earlier, with the FY2024 full-year figure at $9.8 million, changed 0.49% from the prior year.
• Non-Current Deferred Tax Liability was little changed at $9.8 million in Q4 2024 per CRNX's latest filing, from $9.8 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $9.8 million in Q4 2023 and bottomed at $453000.0 in Q4 2022.
• The 3-year median for Non-Current Deferred Tax Liability is $9.8 million (2024), against an average of $6.7 million.
• Across the five-year window, Non-Current Deferred Tax Liability surged 2063.13% in 2023 and fell 0.49% in 2024, its largest moves.
• Year by year, Non-Current Deferred Tax Liability stood at $453000.0 in 2022, then jumped by 2063.13% to $9.8 million in 2023, then dropped by 0.49% to $9.8 million in 2024.
• Per Business Quant, the three latest CRNX Non-Current Deferred Tax Liability figures stand at $9.8 million (Q4 2024), $9.8 million (Q4 2023), and $453000.0 (Q4 2022).